主要肺高血圧:血管生物学と翻訳研究 "進行中の研究"
1Division of Cardiolgy, Department of Medicine, University of Alberta, WMC 2C2.36,8440, Edmonton, Alberta, Canada. sarcher@cha.ab.ca.
Circulation
|November 30, 2000
まとめ
1次性肺高血圧 (PPH) は,血管機能不全と改造を伴う. 研究によると,イオンチャネル欠陥と異常な酵素活性がこの深刻な状態に寄与し,肺血管抵抗に影響を与えると示唆されています.
科学分野:
- 心血管生物学 心血管生物学
- 肺内医学 肺内医学 肺内医学
- 遺伝学 遺伝学とは
背景:
- 一次性肺高血圧 (PPH) は,肺血管抵抗が上昇し,呼吸不全や胸痛などの症状を引き起こす重症である.
- PPHは,染色体2の遺伝因子に関連した家族的な成分を持つことができます.
- この症候群は,前血栓性傾向,内皮機能不全,滑らかな筋肉細胞の変異,アドベンチシャルの改造を含む複雑な血管異常を伴う.
研究 の 目的:
- 主要肺高血圧 (PPH) の根本的なメカニズムを探求する.
- PPHの病原性におけるイオンチャネル,特に電圧誘導カリウムチャネル (Kv) の役割を調査する.
- PPHにおける血管異常に対するマトリックスメタルプロテインアースとエラスタースの活性への寄与を調べる.
主な方法:
- 肺血管生物学の分析,光膜,内皮,滑らかな筋肉細胞,およびアドベンチチアに焦点を当てた.
- 血管および血小板細胞における電圧誘導カリウムチャネル (Kv) 発現および機能の調査.
- 影響を受けた肺血管におけるマトリックスメタルプロテインアースとエラスタースの活性度の評価.
主要な成果:
- 滑らかな筋肉細胞におけるKvチャネルの発現の減少と機能障害は,脱極化とカルシウム過負荷を引き起こし,血管収縮と潜在的増殖を引き起こします.
- 異常なマトリックス金属タンパク質酵素と弾性酵素の活性には,過剰な血管再構成,血管トーン変化,血小板活性化が伴う.
- PPHの病原性は,遺伝的傾向,内皮機能不全などの感受性フェノタイプ,および潜在的な環境トリガーを含む多因性であるようです.
結論:
- 血管および血小板KVチャネルの機能および発現の障害は,PPHがイオンチャネル疾患である可能性があることを示唆しています.
- 異常なマトリックス金属タンパク質酵素と弾性酵素の活性が,血管トーン,血小板活性化,再構成の説明を提供している.
- 現在の治療法により生存率が向上する一方で,PPHは依然として高い死亡率を持つ疾患であり,プロスタサイクリン,酸化窒素合成酵素,KVチャネル,エンドセリン,マトリックス金属タンパク質酵素を標的とした新しい治療法の必要性を強調しています.
関連する概念動画
Pulmonary Hypertension: Classification and Pathogenesis
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Hypertension II: Pathophysiology
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...


